WallStSmart
SGRY

Surgery Partners Inc

NASDAQ: SGRY · HEALTHCARE · MEDICAL CARE FACILITIES

$13.78
+0.22% today

Updated 2026-06-05

Market cap
$1.75B
P/E ratio
P/S ratio
0.52x
EPS (TTM)
$-0.59
Dividend yield
52W range
$11 – $24
Volume
1.4M

Surgery Partners Inc (SGRY) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item20122013201420152016201720182019202020212022202320242025
Operating cash flow$46.38M$49.08M$21.95M$84.48M$125.24M$120.94M$144.60M$129.50M$246.90M$87.10M$158.80M$293.80M$300.10M$274.30M
Capital expenditures$4.69M$4.15M$9.44M$33.44M$39.11M$29.60M$39.80M$73.60M$42.90M$57.60M$80.60M$88.80M$90.40M$78.70M
Depreciation
Stock-based comp$411000.00$455000.00$942000.00$7.50M$2.02M$5.60M$9.34M$10.20M$13.20M$17.40M$18.40M$17.70M$33.30M$14.80M
Free cash flow$41.68M$44.93M$12.51M$51.04M$86.13M$91.34M$104.80M$55.90M$204.00M$29.50M$78.20M$205.00M$209.70M$195.60M
Investing cash flow
Financing cash flow
Dividends paid$131.01M$93.00M$1.32M$85.87M$1.32M$7.80M$121.20M$109.60M$5.10M$146.80M$0.00
Share repurchases
Debt repayment
Net change in cash$-16.99M$11.77M$9.39M$-91.60M$225.20M$71.70M$-107.00M

Frequently asked questions

What is Surgery Partners Inc's revenue?

Surgery Partners Inc's trailing twelve-month revenue is $3.34B. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is SGRY?

In its most recent fiscal year, SGRY ran a gross margin of 23.12%, an operating margin of 11.77%, and a net margin of -2.35%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does SGRY generate?

SGRY produced $195.60M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is SGRY's balance sheet healthy?

SGRY holds $239.90M in cash and equivalents against $3.60B in long-term debt, on $1.71B of shareholder equity. That debt is best read against the cash flow the business throws off each year.